Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)
Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –
Aurinia Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Aurinia Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $48.03M, up 61.6% year over year. For fiscal 2025 it was $32.51M, up 56.4% from the year before. The highest annual figure on record is $52.87M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.51M | +56.4% |
| FY2024 | Dec 31, 2024 | $20.79M | -58.1% |
| FY2023 | Dec 31, 2023 | $49.64M | +10.3% |
| FY2022 | Dec 31, 2022 | $44.99M | -12.0% |
| FY2021 | Dec 31, 2021 | $51.14M | +1.6% |
| FY2020 | Dec 31, 2020 | $50.33M | -4.8% |
| FY2019 | Dec 31, 2019 | $52.87M | +27.8% |
| FY2018 | Dec 31, 2018 | $41.38M | +22.0% |
| FY2017 | Dec 31, 2017 | $33.93M | +133.5% |
| FY2016 | Dec 31, 2016 | $14.53M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $16.61M | +97.0% |
| Q2 FY2026 | Jun 30, 2026 | $13.05M | +75.6% |
| Q1 FY2026 | Mar 31, 2026 | $7.47M | +30.1% |
| Q4 FY2025 | Dec 31, 2025 | $10.90M | +34.4% |
| Q3 FY2025 | Sep 30, 2025 | $8.44M | +176.8% |
| Q2 FY2025 | Jun 30, 2025 | $7.43M | +82.2% |
| Q1 FY2025 | Mar 31, 2025 | $5.74M | +3.5% |
| Q4 FY2024 | Dec 31, 2024 | $8.11M | -20.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.05M | -77.6% |
| Q2 FY2024 | Jun 30, 2024 | $4.08M | -67.7% |
| Q1 FY2024 | Mar 31, 2024 | $5.55M | -57.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.23M | +3.6% |
| Q3 FY2023 | Sep 30, 2023 | $13.61M | +24.0% |
| Q2 FY2023 | Jun 30, 2023 | $12.65M | +9.8% |
| Q1 FY2023 | Mar 31, 2023 | $13.16M | +4.3% |
| Q4 FY2022 | Dec 31, 2022 | $9.87M | -11.5% |
| Q3 FY2022 | Sep 30, 2022 | $10.97M | -45.3% |
| Q2 FY2022 | Jun 30, 2022 | $11.53M | +14.2% |
| Q1 FY2022 | Mar 31, 2022 | $12.62M | +28.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.15M | -15.4% |
| Q3 FY2021 | Sep 30, 2021 | $20.07M | +63.9% |
| Q2 FY2021 | Jun 30, 2021 | $10.09M | -8.9% |
| Q1 FY2021 | Mar 31, 2021 | $9.83M | -28.9% |
| Q4 FY2020 | Dec 31, 2020 | $13.17M | – |
| Q3 FY2020 | Sep 30, 2020 | $12.24M | – |
| Q2 FY2020 | Jun 30, 2020 | $11.08M | – |
| Q1 FY2020 | Mar 31, 2020 | $13.84M | – |
See a number that looks wrong?